Dapagliflozin effectively reduces albuminuria after renin-angiotensin system blockade therapy in patients with T2DM and hypertension, improves glycemic control, reduces systolic blood pressure, and promotes uric acid excretion, thus reducing renal and cardiovascular risks [15]. The gene discussed is REN; the disease is hypertensive disorder.